NCT04697056View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Ichthyosis
Interventions
DRUG

Imsidolimab

Humanized Monoclonal Antibody

BIOLOGICAL

placebo

placebo

Trial Locations (7)

33125

Site 112, Miami

43215

Site 102, Columbus

60611

Site 101, Chicago

78218

Site 107, San Antonio

84132

Site 105, Salt Lake City

94304

Site 106, Palo Alto

06519

Site 104, New Haven

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY